General Information of Drug (ID: DMLVERQ)

Drug Name
Ro-0505124 Drug Info
Synonyms RO0505124
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9911652
CAS Number
CAS 443913-79-9
TTD Drug ID
DMLVERQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [3]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [4]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [5]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [6]
Trilaciclib DMP5A4T Small-cell lung cancer 2C25.Y Approved [7]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [8]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [10]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [11]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Inhibitor [2]
Fused homolog (STK36) TTX5KEQ STK36_HUMAN Inhibitor [1]

References

1 Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. J Biol Chem. 2006 Apr 14;281(15):9987-95.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1976).
3 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
8 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
9 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
10 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
11 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)